Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
; 387(10027): 1540-1550, 2016 Apr 09.
Article
in En
| MEDLINE
| ID: mdl-26712084
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Taxoids
/
Molecular Targeted Therapy
/
Antibodies, Monoclonal, Humanized
/
B7-H1 Antigen
/
Lung Neoplasms
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2016
Type:
Article